107 related articles for article (PubMed ID: 23337362)
1. Analyses on activation of NF-κB and effect of bortezomib in canine neoplastic lymphoid cell lines.
Kojima K; Fujino Y; Goto-Koshino Y; Ohno K; Tsujimoto H
J Vet Med Sci; 2013; 75(6):727-31. PubMed ID: 23337362
[TBL] [Abstract][Full Text] [Related]
2. Bortezomib induces nuclear translocation of IκBα resulting in gene-specific suppression of NF-κB--dependent transcription and induction of apoptosis in CTCL.
Juvekar A; Manna S; Ramaswami S; Chang TP; Vu HY; Ghosh CC; Celiker MY; Vancurova I
Mol Cancer Res; 2011 Feb; 9(2):183-94. PubMed ID: 21224428
[TBL] [Abstract][Full Text] [Related]
3. Down-regulating constitutive activation of the NF-kappaB canonical pathway overcomes the resistance of cutaneous T-cell lymphoma to apoptosis.
Sors A; Jean-Louis F; Pellet C; Laroche L; Dubertret L; Courtois G; Bachelez H; Michel L
Blood; 2006 Mar; 107(6):2354-63. PubMed ID: 16219794
[TBL] [Abstract][Full Text] [Related]
4. Bortezomib-induced apoptosis with limited clinical response is accompanied by inhibition of canonical but not alternative nuclear factor-{kappa}B subunits in head and neck cancer.
Allen C; Saigal K; Nottingham L; Arun P; Chen Z; Van Waes C
Clin Cancer Res; 2008 Jul; 14(13):4175-85. PubMed ID: 18593997
[TBL] [Abstract][Full Text] [Related]
5. The proteasome inhibitor bortezomib inhibits the growth of canine malignant melanoma cells in vitro and in vivo.
Ito K; Kobayashi M; Kuroki S; Sasaki Y; Iwata T; Mori K; Kuroki T; Ozawa Y; Tetsuka M; Nakagawa T; Hiroi T; Yamamoto H; Ono K; Washizu T; Bonkobara M
Vet J; 2013 Dec; 198(3):577-82. PubMed ID: 24035468
[TBL] [Abstract][Full Text] [Related]
6. The proteasome inhibitor bortezomib reverses P-glycoprotein-mediated leukemia multi-drug resistance through the NF-kappaB pathway.
Wang H; Wang X; Li Y; Liao A; Fu B; Pan H; Liu Z; Yang W
Pharmazie; 2012 Feb; 67(2):187-92. PubMed ID: 22512091
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma.
Yang DT; Young KH; Kahl BS; Markovina S; Miyamoto S
Mol Cancer; 2008 May; 7():40. PubMed ID: 18489772
[TBL] [Abstract][Full Text] [Related]
8. NF-kappaB-independent down-regulation of XIAP by bortezomib sensitizes HL B cells against cytotoxic drugs.
Kashkar H; Deggerich A; Seeger JM; Yazdanpanah B; Wiegmann K; Haubert D; Pongratz C; Krönke M
Blood; 2007 May; 109(9):3982-8. PubMed ID: 17185461
[TBL] [Abstract][Full Text] [Related]
9. Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma.
Sartore-Bianchi A; Gasparri F; Galvani A; Nici L; Darnowski JW; Barbone D; Fennell DA; Gaudino G; Porta C; Mutti L
Clin Cancer Res; 2007 Oct; 13(19):5942-51. PubMed ID: 17908991
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib-enhanced radiosensitization through the suppression of radiation-induced nuclear factor-κB activity in human oral cancer cells.
Tamatani T; Takamaru N; Hara K; Kinouchi M; Kuribayashi N; Ohe G; Uchida D; Fujisawa K; Nagai H; Miyamoto Y
Int J Oncol; 2013 Mar; 42(3):935-44. PubMed ID: 23340716
[TBL] [Abstract][Full Text] [Related]
11. NF-kappaB inhibition through proteasome inhibition or IKKbeta blockade increases the susceptibility of melanoma cells to cytostatic treatment through distinct pathways.
Amschler K; Schön MP; Pletz N; Wallbrecht K; Erpenbeck L; Schön M
J Invest Dermatol; 2010 Apr; 130(4):1073-86. PubMed ID: 19940859
[TBL] [Abstract][Full Text] [Related]
12. The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines.
Strauss SJ; Higginbottom K; Jüliger S; Maharaj L; Allen P; Schenkein D; Lister TA; Joel SP
Cancer Res; 2007 Mar; 67(6):2783-90. PubMed ID: 17363600
[TBL] [Abstract][Full Text] [Related]
13. IKKβ inhibitor in combination with bortezomib induces cytotoxicity in breast cancer cells.
Hideshima H; Yoshida Y; Ikeda H; Hide M; Iwasaki A; Anderson KC; Hideshima T
Int J Oncol; 2014 Apr; 44(4):1171-6. PubMed ID: 24481412
[TBL] [Abstract][Full Text] [Related]
14. N-(4-hydroxyphenyl)retinamide inhibits invasion, suppresses osteoclastogenesis, and potentiates apoptosis through down-regulation of I(kappa)B(alpha) kinase and nuclear factor-kappaB-regulated gene products.
Shishodia S; Gutierrez AM; Lotan R; Aggarwal BB
Cancer Res; 2005 Oct; 65(20):9555-65. PubMed ID: 16230421
[TBL] [Abstract][Full Text] [Related]
15. Dynamic effect of bortezomib on nuclear factor-kappaB activity and gene expression in tumor cells.
Sung MH; Bagain L; Chen Z; Karpova T; Yang X; Silvin C; Voss TC; McNally JG; Van Waes C; Hager GL
Mol Pharmacol; 2008 Nov; 74(5):1215-22. PubMed ID: 18684839
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis.
Pham LV; Tamayo AT; Yoshimura LC; Lo P; Ford RJ
J Immunol; 2003 Jul; 171(1):88-95. PubMed ID: 12816986
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib inhibits proteasomal degradation of IκBα and induces mitochondrial dependent apoptosis in activated B-cell diffuse large B-cell lymphoma.
Bu R; Hussain AR; Al-Obaisi KA; Ahmed M; Uddin S; Al-Kuraya KS
Leuk Lymphoma; 2014 Feb; 55(2):415-24. PubMed ID: 23697845
[TBL] [Abstract][Full Text] [Related]
18. TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities.
Sagawa M; Tabayashi T; Kimura Y; Tomikawa T; Nemoto-Anan T; Watanabe R; Tokuhira M; Ri M; Hashimoto Y; Iida S; Kizaki M
Cancer Sci; 2015 Apr; 106(4):438-46. PubMed ID: 25613668
[TBL] [Abstract][Full Text] [Related]
19. A novel NF-κB inhibitor improves glucocorticoid sensitivity of canine neoplastic lymphoid cells by up-regulating expression of glucocorticoid receptors.
Matsuda A; Tanaka A; Muto S; Ohmori K; Furusaka T; Jung K; Karasawa K; Okamoto N; Oida K; Itai A; Matsuda H
Res Vet Sci; 2010 Dec; 89(3):378-82. PubMed ID: 20362310
[TBL] [Abstract][Full Text] [Related]
20. Specific effects of bortezomib against experimental malignant pleural effusion: a preclinical study.
Psallidas I; Karabela SP; Moschos C; Sherrill TP; Kollintza A; Magkouta S; Theodoropoulou P; Roussos C; Blackwell TS; Kalomenidis I; Stathopoulos GT
Mol Cancer; 2010 Mar; 9():56. PubMed ID: 20219102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]